Navigation Links
Royalty Pharma Statement Regarding Elan Proposal
Date:3/6/2013

p>A breakdown of these entities' revenues by therapeutic area may be found in Appendix V.

Important noticeThe Proposal is subject to the following pre-conditions, which will need to be satisfied or waived prior to any announcement of the Possible Offer under Rule 2.5 of the Irish Takeover Rules:

  (i)
being granted access to and completion of satisfactory due diligence into the business of Elan, including management meetings;

 (ii)
no acquisitions, dispositions, restructuring activities, debt refinancing, stock buybacks or other extraordinary transactions by Elan apart from the completion of the Tysabri Transaction;

(iii)
the Tysabri Transaction shall have closed and the terms shall not have been amended or altered in any material respect from the terms announced on February 6, 2013;

(iv)
unanimous recommendation of the Possible Offer, if made, by the directors of Elan;

 (v)
each of the directors of Elan giving firm irrevocable undertakings to accept the Possible Offer, if made, or to vote in favour of the scheme of arrangement (as applicable) in respect of all the Elan Stock in which they have an interest;

(vi)
the entry into an expense reimbursement agreement in a form acceptable to Royalty Pharma in respect of an amount equal to the maximum allowable under the terms of the Irish Takeover Rules and the financial advisor to Elan confirming to the Irish Takeover Panel that such agreement is in the best interests of Elan's Shareholders;

(vii)
Elan's assistance, as appropriate, in obtaining support from its major institutional shareholders for the Possible Offer, if made; and

(viii)
execution of an appropriate implementation agreement to govern the conduct of a scheme of arrangement if the transaction is to be structured in that manner.

Royalty Pharma reserves the right to waive any or all of the pre-conditions described in this announcement and to implement
'/>"/>

SOURCE RP Management, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
2. Cowen Healthcare Royalty Partners Raises $1 Billion
3. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
4. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz
5. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
6. AVANIR Pharmaceuticals To participate in two conferences in March
7. Favorable Scenario for Japan Pharma Industry in Coming Years, New Report Says
8. Hyperion Wins NDA Approval for UCD Drug Developed With Support from PharmaDirections
9. Technical Analysis on VIVUS and Achillion Pharma: Highlights on These Biotech Companies
10. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
11. Serialization in Pharmaceuticals, a Webinar Presented by Xtalks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... YORK , July 28, 2015 People ... by hearing aids achieved significant and sometimes profound improvements ... cochlear implant devices, according to a new multicenter study ... In the study, described online ahead of print in ... medical centers and private clinics in the ...
(Date:7/28/2015)... DUBLIN , July 21, 2015 ... ) has announced the addition of the ... report to their offering. Globally, ... applications including immuno-phenotyping, cell proliferation, cancer, and stem ... in clinical applications primarily because of demand from ...
(Date:7/28/2015)... 28, 2015 Deerfield Management Company, L.P. today ... L.P., which will invest in groundbreaking advancements in science ... cancer, and orphan diseases. The venture capital fund will ... are developed and improve the way healthcare is delivered ... largest healthcare-focused venture funds in the sector, will donate ...
(Date:7/28/2015)... N.J. , July 28, 2015  Moerae ... second Phase 1 clinical trial with MMI-0100, a ... is being developed for pulmonary disorders characterized by ... United Kingdom , is a ... further evaluating the safety and tolerability of MMI-0100 ...
Breaking Biology Technology:Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2
... Ohio and LOD, Israel, November 3 Simbionix,USA ... hands-on,curriculum for training medical professionals, today announced that ... US Marketing Director on,November 10th, 2008. Gary Zamler, ... Simbionix has enjoyed double digit revenue growth in,both ...
... Telomolecular CEO, Matthew Sarad, clarifies the scope and terms of his ... ... (PRWEB) November 3, 2008 -- Telomolecular, a Rancho Cordova, California Corporation, ... therapeutics to treat diseases of aging and cancer, particularly diseases related ...
... compound in sufficient and rapidly produced yields, potentially ... could boost semiconductor capabilities for large-area applications. , ... the first heterometallic gallium-indium hydroxide nanocluster was the ... of nitrosobenzene. , The substitute was identified during ...
Cached Biology Technology:William E. Lewandowski to Lead Simbionix US Marketing Team in Simbionix's Strategic Expansion in the US Market 2Former Telomolecular CEO Clarifies SEC Settlement 2Former Telomolecular CEO Clarifies SEC Settlement 3New nanocluster to boost thin films for semiconductors 2
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
(Date:7/7/2015)... -- Research and Markets ( ... "Capacitive Fingerprint Sensors Patent Landscape" report ... fingerprint sensing technology is the most reliable and ... developed. This patent landscape focuses on fingerprint sensors ... of capacitive fingerprint sensors is closely linked to ...
(Date:7/2/2015)... 2015 Research and Markets( ... "Next Generation Biometrics Market by Application, Technology, Function & ... their offering. The next generation biometrics market ... a CAGR of 17.9% between 2015 and 2020 ... the market. Safran SA ( France ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... HOLE, MATiny, toxic protein particles severely disrupt neurotransmission and ... separate studies by Marine Biological Laboratory (MBL) researchers have ... beta, which has long been known to accumulate and ... "These small particles that haven,t aggregated into plaquesthese ...
... A University of Florida scientist whose interest in ... molecular building blocks that shape appendages ranging from feet ... Early Career Scientist today (Thursday, March 26), a distinction ... Martin Cohn, a developmental biologist and a member ...
... A material developed at the Hebrew University of ... following surgery has led to approval by the U.S. ... use in pediatric cardiac surgery patients. The ... of novel, tailor-made, biodegradable polymers for the prevention of ...
Cached Biology News:Tiny but toxic: MBL researchers discover a mechanism of neurodegeneration in Alzheimer's disease 2UF scientist tapped by Howard Hughes Medical Institute to pursue 'best ideas' 2UF scientist tapped by Howard Hughes Medical Institute to pursue 'best ideas' 3Hebrew University professor's work leads to FDA approval for product 2
... Thermomixer R offers maximum application versatility ... heating, and cooling. Its active heating/cooling ... and temperature control ranges. Five different ... micro test tubes, are available for: ...
... Protein DetectorTM Microarray Dot Blot Kits overcome ... and quantitation over a wide range in ... ) detection. They are ideal for ... hundreds of samples for the presence of ...
... a high quality microarray scanner based on patented ... and spatial resolution. The DNAscope LM is ... microarray scanner that is upgradeable to a total ... Includes control module (computer), monitor, ...
... Protein DetectorTM Microarray Dot Blot Kits ... accuracy and quantitation over a wide range ... formats ) detection. They are ideal ... profiling hundreds of samples for the presence ...
Biology Products: